Martijn Ramon Brands

Martijn Ramon Brands

Auto-generated profile, based on publicly available information

Martijn Ramon Brands

Amsterdam UMC Location University of Amsterdam, Emma Children's Hospital, Paediatric Hematology, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2022 in Journal of Medical Internet Research
Verified
Journal Article
Open access
MBMartijn R Brands
Martijn R Brands
SGSamantha C Gouw
Samantha C Gouw
MBMolly Beestrum
Molly Beestrum
RCRobert M Cronin
Robert M Cronin
KFKarin Fijnvandraat
Karin Fijnvandraat
Sherif M. BadawySherif M. Badawy
Sherif M. Badawy
Background: eHealth tools such as patient portals and personal health records, also known as patient-centered digital health records, can engage and empower individuals with chronic health conditions. Patients who are highly engaged in their care have improved disease knowledge, self-management skills, and clinical outcomes. Objective: We aimed to systematically review the effects of patient-centered digital health records on clinical and patient-reported outcomes, health care utilization, and satisfaction among patients with chronic conditions and to assess the feasibility and acceptability of their use. Methods: We searched MEDLINE, Cochrane, CINAHL, Embase, and PsycINFO databases between January 2000 and December 2021. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines were followed. Eligible studies were those evaluating digital health records intended for nonhospitalized adult or pediatric patients with a chronic condition. Patients with a high disease burden were a subgroup of interest. Primary outcomes included clinical and patient-reported health outcomes and health care utilization. Secondary outcomes included satisfaction, feasibility, and acceptability. Joanna Briggs Institute critical appraisal tools were used for quality assessment. Two reviewers screened titles, abstracts, and full texts. Associations between health record use and outcomes were categorized as beneficial, neutral or clinically nonrelevant, or undesired. Results: Of the 7716 unique publications examined, 81 (1%) met the eligibility criteria, with a total of 1,639,556 participants across all studies. The most commonly studied diseases included diabetes mellitus (37/81, 46%), cardiopulmonary conditions (21/81, 26%), and hematology-oncology conditions (14/81, 17%). One-third (24/81, 30%) of the studies were randomized controlled trials. Of the 81 studies that met the eligibility criteria, 16 (20%) were of high methodological quality. Reported outcomes varied across studies. The benefits of patient-centered digital health records were most frequently reported in the category health care utilization on the “use of recommended care services” (10/13, 77%), on the patient-reported outcomes “disease knowledge” (7/10, 70%), “patient engagement” (13/28, 56%), “treatment adherence” (10/18, 56%), and “self-management and self-efficacy” (10/19, 53%), and on the clinical outcome “laboratory parameters,” including HbA1c and low-density lipoprotein (LDL; 16/33, 48%). Beneficial effects on “health-related quality of life” were seen in only 27% (4/15) of studies. Patient satisfaction (28/30, 93%), feasibility (15/19, 97%), and acceptability (23/26, 88%) were positively evaluated. More beneficial effects were reported for digital health records that predominantly focus on active features. Beneficial effects were less frequently observed among patients with a high disease burden and among high-quality studies. No unfavorable effects were observed. Conclusions: The use of patient-centered digital health records in nonhospitalized individuals with chronic health conditions is potentially associated with considerable beneficial effects on health care utilization, treatment adherence, and self-management or self-efficacy. However, for firm conclusions, more studies of high methodological quality are required. Trial Registration: PROSPERO (International Prospective Register of Systematic Reviews) CRD42020213285; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=213285

23 February 2019 in Archives of Disease in Childhood
Verified
Journal Article
Open access
PDF file
MBMartijn Ramon Brands
Martijn Ramon Brands
EVEls Van de Vijver
Els Van de Vijver
SHSjoukje Marije Haisma
Sjoukje Marije Haisma
AHAnke Heida
Anke Heida
Patrick F. van RheenenPatrick F. van Rheenen
Patrick F. van Rheenen
Objective: To study the association between Dientamoebafragilis colonisation and faecal calprotectin to see whether the parasite is a harmless commensal or a gut pathogen.Design: Cross-sectional study of previously collected stool samples.Setting and patients: Two hundred stool samples originated from children aged 5–19 years with chronic abdominal pain and diarrhoea, who were seen in paediatric clinics in the Netherlands and Belgium and in whom somatic gastrointestinal disorders were excluded. Another 122 samples came from a healthy community-based reference population of the same age. All stool samples were analysed with real-time PCR for the detection of D. fragilis and with an ELISA for calprotectin—a biomarker of gastrointestinal inflammation.Main outcome measures: Prevalence of D. fragilis colonisation and results of stool calprotectin testing.Results: D. fragilis was detected in 45% (95% CI 38% to 51%) of patients and in 71% (95% CI 63% to 79%) of healthy children. Median (IQR) concentrations of calprotectin in patients and healthy children with a positive PCR result were not different from those with a negative PCR result (40 (40–55) μg/g vs 40 (40–75) μg/g, respectively).Conclusion: Since D. fragilis colonisation is most prevalent in healthy children and is not associated with an increase in faecal calprotectin concentration, our data do not support the inference that D. fragilis is a pathogenic parasite. Routinely testing for D. fragilis in children with chronic abdominal pain should therefore be discouraged.

27 February 2025 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
MBMartijn R. Brands
Martijn R. Brands
ETElisabeth M. Taal
Elisabeth M. Taal
MVMartijn Oude Voshaar
Martijn Oude Voshaar
MDMariëtte H.E. Driessens
Mariëtte H.E. Driessens
CVCaroline M.E. van Veen
Caroline M.E. van Veen
SGSamantha C. Gouw
Samantha C. Gouw
People with hemophilia in the Netherlands log bleeds and infusions through a digital treatment diary. With the current innovations in hemophilia treatments, the use of patient-reported bleeding data will become increasingly important. To assess real-world bleeding rates on emicizumab in a nationwide cohort of people with severe hemophilia A, and assess the value of digital treatment diary data. People with severe hemophilia A of all ages with and without inhibitors using emicizumab who use the digital treatment diary were included. From 2018 to October 2023, data on bleeds treated with clotting factor concentrate were collected from digital treatment diaries and electronic health records. Mean (95% CI) annualized (joint) bleeding rates were calculated using negative-binomial regression analyses. Proportions of people with zero-treated (joint) bleeds were assessed using Kaplan–Meier survival analysis. We calculated the proportion of all bleeds that were recorded in digital treatment diaries. The 232 included persons (median age, 27 years; IQR, 13-51) who used emicizumab for a median of 27 months (IQR, 14-31 months). The mean treated annualized bleeding rate and annualized joint bleeding rate were 1.5 (CI, 1.3-1.8) and 0.8 (CI, 0.6-1.0), respectively. At 24 weeks, 63% had zero-treated bleeds, and 80% had zero-treated joint bleeds. Of treated bleeds, 67% (310/460) were reported in digital treatment diaries. Bleeding rates among Dutch people with severe hemophilia A using emicizumab were comparable to other real-world studies. We formulated recommendations to improve the quality of patient-reported bleeding data, such as establishing guidelines for recording bleeds and improving interoperability.

1 April 2021 in BMJ Case Reports
Verified
Journal Article
Open access
PDF file
MBMartijn R Brands
Martijn R Brands
JSJelmer Sytema
Jelmer Sytema
MHMarinus van Hulst
Marinus van Hulst
AKArvid Wa Kamps
Arvid Wa Kamps
Acute intoxication with a vitamin K antagonist may cause serious coagulopathy. We report the accidental ingestion of a high dose of acenocoumarol in a young child. Two intravenous administrations of 5 mg of vitamin K, in combination with fast and repeated administration of activated charcoal and sodium sulfate, were sufficient to prevent coagulopathy and related symptoms, despite a confirmed elevated blood acenocoumarol concentration (260 µg/L).

2 September 2025 in Haemophilia
Verified
Journal Article
Open access
MBMartijn R. Brands
Martijn R. Brands
LBLieke Baas
Lieke Baas
MDMariette H. Driessens
Mariette H. Driessens
SGSamantha C. Gouw
Samantha C. Gouw
RGRieke van der Graaf
Rieke van der Graaf
KMKarina Meijer
Karina Meijer
Background: People with haemophilia perform various self‐management tasks, supported by multiple health apps. Personal health records will enable individuals to access and add health information from different institutions in a single digital tool, providing an integrated overview of data. Later, individuals will also be able to share their data with health care providers and relatives. This creates a new role for users: Coordinator of data exchange. Objective: To analyze if and how personal health records contribute to self‐management, with a particular emphasis on the role of coordinating data exchange. Methods: We applied various interpretations of self‐management to the promises of personal health records to identify what goals it intends to achieve. We then assessed various skills and responsibilities that are required from users to work with personal health records. Last, we analyzed potential scenarios of the coordination of data exchange. Results: Personal health records promise to support both compliant self‐management (i.e., managing care according to medical regimens) and concordant self‐management (i.e., managing care according to personal values and goals). Which of these forms is promoted depends on the goal of data coordinating tasks. The chosen design of the data sharing feature may impact the usability and accessibility of personal health records for a wide group of users. Conclusion: What form of self‐management is promoted by personal health records needs to be more clearly defined. A participatory design strategy can ensure that the design of coordinating data exchange matches individuals’ and health care providers’ needs.

21 August 2023 in Haemophilia
Verified
Journal Article
Open access
MBMartijn R. Brands
Martijn R. Brands
EJEbony A. M. Janssen
Ebony A. M. Janssen
MCMarjon H. Cnossen
Marjon H. Cnossen
CSCees Smit
Cees Smit
LVLize van Vulpen
Lize van Vulpen
SGSamantha C. Gouw
Samantha C. Gouw
Introduction: Care for adolescents with haemophilia is transferred from paediatric to adult care around the age of 18 years. Transition programs help to prepare adolescents for this transfer and prevent declining treatment adherence. Evaluating transition readiness may identify areas for improvement.Objective: Assess transition readiness among Dutch adolescents and young adults with haemophilia, determine factors associated with transition readiness, and identify areas of improvement in transition programs.Methods: All Dutch adolescents and young adults aged 12–25 years with haemophilia were invited to participate in a nationwide questionnaire study. Transition readiness was assessed using multiple‐choice questions and was defined as being ready or almost ready for transition. Potential factors associated with transition readiness were investigated, including: socio‐demographic and disease‐related factors, treatment adherence, health‐related quality of life, and self‐efficacy.Results: Data of 45 adolescents and 84 young adults with haemophilia (47% with severe haemophilia) were analyzed. Transition readiness increased with age, from 39% in 12–14 year‐olds to 63% in 15–17 year‐olds. Nearly all post‐transition young adults (92%, 77/84) reported they were ready for transition. Transition readiness was associated with treatment adherence, as median VERITAS‐Pro treatment adherence scores were worse in patients who were not ready (17, IQR 9–29), compared to those ready for transition (11, IQR 9–16). Potential improvements were identified: getting better acquainted with the adult treatment team prior to transition and information on managing healthcare costs.Conclusions: Nearly all post‐transition young adults reported they were ready for transition. Improvements were identified regarding team acquaintance and preparation for managing healthcare costs.